Panalgo Blog

Press-for-ICERs-Value-Based-Pricing-Assessments
ICER

ICER Versus NICE: Who Cares About Value-Based Pricing Assessments?

This is my last post in an ICER versus NICE series that examines how ICER’s and NICE’s methodologies for implementing cost-effectiveness (CE) analyses differ. My last post explored how differences in the use of a fixed CE threshold and the application of a narrower CE threshold range may lead to different intervention recommendations. In this[…]

ICERvsNICEvenndiagram-300x169
ICER

ICER vs. NICE: Three Key Differences in Approach and Appraisal

Back in December, I recapped an issues panel titled, “Should ICER be NICE (or Not)?” from ISPOR’s 20th Annual European Congress, which sought to compare the use of ICER’s value assessment framework versus NICE’s guidelines when conducting and interpreting cost-effectiveness (CE) analyses. In that post, I summarized the ideas expressed during the[…]

ICERversusNICEpanelatISPOREU-300x225
ICER

ICER Versus NICE: The Verdict From Our ISPOR Glasgow Issue Panel

A smashing success! ISPOR hosted its 20th Annual European Congress in Glasgow, Scotland last month, boasting nearly 5,000 attendees and satisfying our deepest sweet tooth cravings thanks to the lunch menu’s endless supply of teacake biscuits, caramel wafers, caramel shortbread, and IRN Bru. In addition, the conference hosted three well-attended[…]

CEA-Framework-683x1024
ICER

Should ICER Be NICE (or Not)?: A Prelude to Our ISPOR Glasgow Issue Panel

ISPOR’s 20th Annual European Congress in Glasgow is fast approaching, with the first plenary session scheduled for this Monday, November 6th. I will be attending as part of BHE’s team and am looking forward to the plenary sessions discussing the evolution of value in healthcare, including the increase in value-based care initiatives, the future of[…]

Drug Pricing

Policy Corner: The Mysterious World of Drug Pricing

Almost every day, I see unflattering news stories regarding drug pricing and the cost of pharmaceuticals. Whether it's a supplier raising the costs of essential drugs like the Epi-Pen several-fold or a new CAR-T drug priced at a seemingly exorbitant rate - not unlike a three-bedroom house here in the Boston area - media and government scrutiny is[…]

Instant Health Data

Put reliable, rapid analytics in the hands of more people across your organization

Learn more about Panalgo

Get the story behind our work and our team.